查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947932

个人化基因治疗市场分析及预测（至2035年）：依类型、产品、服务、技术、应用、最终使用者、流程、部署及阶段划分

Personalized Gene Therapies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Deployment, Stage
出版日期: | 出版商: Global Insight Services | 英文 354 Pages | 商品交期: 3-5个工作天内

价格
简介目录

个人化基因治疗市场预计将从2024年的12亿美元成长到2034年的58亿美元，复合年增长率约为20.7%。个人化基因治疗市场是指根据个体基因谱量身定制的治疗方法，旨在纠正遗传疾病的根本原因。该市场整合了先进的基因组学、生物资讯学和生物技术，以开发客製化治疗方法，从而提高疗效并最大限度地减少副作用。遗传疾病盛行率的上升以及CRISPR和基因编辑技术的进步是推动市场成长的主要因素。关键趋势包括监管核准的增加以及生物技术公司之间为加速创新和提高可及性而开展的合作。

个人化基因治疗市场正经历强劲成长，这主要得益于基因组学的进步和对客製化治疗日益增长的需求。肿瘤领域成长最为迅猛，这主要源自于对标靶癌症治疗以改善患者预后的需求。 CAR-T细胞疗法和基因编辑技术处于肿瘤领域的前沿，展现出巨大的创新和疗效潜力。罕见疾病领域也紧随其后，个人化治疗为那些治疗选择有限的疾病带来了希望。基因替代疗法和RNA治疗方法作为解决疾病潜在遗传病因的手段，正日益受到关注。心血管领域，特别是针对心臟疾病的基因治疗，也成为一个充满前景的领域，目前相关研究和临床试验正在进行中。对先进递送系统和监管支援的投资进一步推动了市场成长。生技公司和研究机构之间日益密切的合作有望加速治疗方法的研发，为相关人员带来盈利的回报。

市场区隔
类型 体细胞基因治疗、生殖细胞基因治疗、体内基因治疗、体外基因治疗
产品 病毒载体、非病毒载体、基因编辑工具、质体DNA、RNA疗法
服务 基因筛检、诊断、客製化基因合成​​、临床试验和监管支持
科技 CRISPR、TALENs、锌指核酸酶、反义寡核苷酸、 RNA干扰
目的 肿瘤科、罕见疾病科、心血管疾病科、神经系统疾病科、眼科、代谢性疾病科
最终用户 医院、生技公司、製药公司、研究机构、学术机构
流程 基因转殖、基因编辑、基因静默、基因替换
部署 临床、商业、研究
步 药物发现、临床前试验、临床试验、商业化

在个人化基因治疗市场，市场占有率日益受到主要企业定价策略和创新产品推出的影响。各公司致力于透过价格竞争来抢占市场份额，同时持续投资于新型治疗方法的研发。这导致新产品上市数量激增，拓展了治疗选择，并推动了市场发展。该市场的特点是策略竞争，各公司竞相推出治疗方法以满足未满足的医疗需求，从而实现盈利成长。竞争基准分析显示，市场竞争异常激烈，成熟企业和新兴生技公司都在争夺主导地位。监管影响，尤其是在北美和欧洲，在塑造市场动态发挥关键作用。这些地区制定了严格的标准，影响企业的市场准入和扩大策略。竞争格局的特点是策略联盟、併购，旨在加强产品平臺并扩大地理覆盖范围。监管发展、技术进步和策略伙伴关係将共同塑造市场的未来，并带来巨大的成长潜力。

主要趋势和驱动因素：

个人化基因治疗市场正经历显着成长，这主要得益于基因组技术的进步和精准医疗领域投资的不断增加。人工智慧（AI）和机器学习在基因治疗研究中的应用是关键趋势，它提高了治疗方案开发的准确性和效率。此外，生物技术公司与学术机构之间的合作正在加速创新并推动市场发展。监管部门对基因治疗核准的支持也是关键驱动因素，简化的核准流程有助于加速产品进入市场。遗传性疾病和罕见疾病的日益普遍凸显了个人化治疗的必要性，进一步推动了市场需求。此外，以患者为中心的治疗理念也日益受到关注，强调个别化治疗能够改善治疗效果并提高患者满意度。新兴市场拥有日益完善的医疗基础设施和不断提高的基因治疗意识，因此蕴藏着巨大的机会。能够成功应对监管环境并提供高性价比解决方案的公司有望占据显着的市场份额。在技​​术突破和对个人化医疗的关注推动下，个人化基因治疗市场预计将持续成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 体细胞基因治疗
    • 种系基因治疗
    • 体内基因治疗
    • 体外基因治疗
  • 市场规模及预测：依产品划分
    • 病毒载体
    • 非病毒载体
    • 基因编辑工具
    • 质体DNA
    • RNA疗法
  • 市场规模及预测：依服务划分
    • 基因筛检
    • 咨询
    • 客製化基因合成
    • 临床试验
    • 监管支持
  • 市场规模及预测：依技术划分
    • CRISPR
    • TALENs
    • 锌指核酸酶
    • 反义寡核苷酸
    • RNA干扰
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 罕见疾病
    • 心血管疾病
    • 神经系统疾病
    • 眼科
    • 代谢性疾病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 生技公司
    • 製药公司
    • 研究所
    • 学术机构
  • 市场规模及预测：依製程划分
    • 基因转移
    • 基因编辑
    • 基因静默
    • 基因替换
  • 市场规模及预测：依发展状况
    • 临床
    • 商业
    • 研究
  • 市场规模及预测：依阶段划分
    • 药物发现
    • 临床前
    • 临床试验
    • 商业化

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Bluebird Bio
  • Sangamo Therapeutics
  • uni Qure
  • REGENXBIO
  • Krystal Biotech
  • Orchard Therapeutics
  • Logic Bio Therapeutics
  • Passage Bio
  • Intellia Therapeutics
  • Editas Medicine
  • Beam Therapeutics
  • Precision Bio Sciences
  • CRISPR Therapeutics
  • Rubius Therapeutics
  • Homology Medicines
  • Repligen
  • Voyager Therapeutics
  • Cellectis
  • Meira GTx
  • Freeline Therapeutics

第九章：关于我们

简介目录
Product Code: GIS32578

Personalized Gene Therapies Market is anticipated to expand from $1.2 billion in 2024 to $5.8 billion by 2034, growing at a CAGR of approximately 20.7%. The Personalized Gene Therapies Market encompasses treatments tailored to individual genetic profiles, aiming to correct genetic disorders at their source. This market integrates advanced genomics, bioinformatics, and biotechnology to develop bespoke therapies, enhancing efficacy and minimizing side effects. Rising prevalence of genetic disorders and advancements in CRISPR and gene editing technologies are propelling growth. Key trends include increasing regulatory approvals and collaborations among biotech firms to accelerate innovation and accessibility.

The Personalized Gene Therapies Market is experiencing robust growth, propelled by advancements in genomics and increasing demand for tailored treatments. The oncology segment leads in performance, driven by the need for targeted cancer therapies that improve patient outcomes. Within oncology, CAR-T cell therapies and gene editing techniques are at the forefront, offering significant potential for innovation and effectiveness. The rare diseases sub-segment follows closely, as personalized approaches offer hope for conditions with limited treatment options. Gene replacement and RNA-based therapies are gaining prominence, addressing the underlying genetic causes of these diseases. The cardiovascular segment, focusing on gene therapies for heart conditions, is also emerging as a promising area, with ongoing research and clinical trials. Investments in advanced delivery systems and regulatory support are further accelerating market growth. The increasing collaboration between biotech firms and research institutions is poised to enhance therapeutic development, offering lucrative opportunities for stakeholders.

Market Segmentation
TypeSomatic Gene Therapy, Germline Gene Therapy, In Vivo Gene Therapy, Ex Vivo Gene Therapy
ProductViral Vectors, Non-Viral Vectors, Gene Editing Tools, Plasmid DNA, RNA Therapeutics
ServicesGenetic Screening, Consulting, Custom Gene Synthesis, Clinical Trials, Regulatory Support
TechnologyCRISPR, TALENs, Zinc Finger Nucleases, Antisense Oligonucleotides, RNA Interference
ApplicationOncology, Rare Diseases, Cardiovascular, Neurological Disorders, Ophthalmology, Metabolic Disorders
End UserHospitals, Biotechnology Companies, Pharmaceutical Companies, Research Institutes, Academic Institutions
ProcessGene Delivery, Gene Editing, Gene Silencing, Gene Replacement
DeploymentClinical, Commercial, Research
StageDiscovery, Preclinical, Clinical Trials, Commercialization

In the Personalized Gene Therapies Market, market share is increasingly influenced by the pricing strategies of key players and the introduction of innovative products. Companies are focusing on competitive pricing to capture market share, while simultaneously investing in the research and development of novel therapies. This dynamic has led to a surge in new product launches, enhancing treatment options and driving market evolution. The landscape is marked by a strategic race to introduce therapies that address unmet medical needs, thus opening lucrative avenues for growth. Competition benchmarking reveals a highly competitive environment with established players and emerging biotech firms vying for dominance. Regulatory influences, particularly in North America and Europe, play a pivotal role in shaping market dynamics. These regions set stringent standards that impact market entry and expansion strategies. The competitive landscape is characterized by strategic collaborations, mergers, and acquisitions aimed at enhancing product pipelines and expanding geographical reach. The market's future is shaped by regulatory developments, technological advancements, and strategic partnerships, promising significant growth potential.

Geographical Overview:

The personalized gene therapies market is witnessing notable growth across various regions, each exhibiting unique dynamics. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in genetic research. The presence of key biotech firms and supportive regulatory frameworks further accelerates the market's expansion. Europe follows closely, with strong governmental support for personalized medicine and a robust research ecosystem. The region's emphasis on precision healthcare and patient-centric approaches enhances its market position. In Asia Pacific, the market is burgeoning, propelled by rising healthcare expenditures and increasing awareness of personalized therapies. Countries like China and India are emerging as significant players due to their large patient pools and growing biotech sectors. Latin America and the Middle East & Africa present promising growth pockets. In Latin America, increasing investments in healthcare innovation are evident, while the Middle East & Africa are recognizing the potential of personalized gene therapies to address regional health challenges effectively.

Global tariffs and geopolitical tensions are significantly impacting the Personalized Gene Therapies Market. In Japan and South Korea, reliance on imported raw materials for gene therapy vectors is prompting strategic investments in local biomanufacturing capabilities to mitigate tariff-induced costs. China is accelerating its domestic biotech sector, driven by export restrictions and a push for self-sufficiency in gene-editing technologies. Taiwan, with its advanced biotech infrastructure, remains pivotal but is vulnerable to cross-strait tensions. The global market for personalized gene therapies is expanding, driven by technological advancements and increasing demand for tailored treatments. By 2035, the market is expected to evolve with stronger regional collaborations and innovation hubs. Middle East conflicts may indirectly affect supply chains through fluctuating energy prices, impacting operational costs and logistics.

Key Trends and Drivers:

The personalized gene therapies market is experiencing a remarkable surge, propelled by advancements in genomic technologies and increasing investment in precision medicine. A key trend is the integration of artificial intelligence and machine learning in gene therapy research, enhancing the accuracy and efficiency of treatment development. Additionally, collaborations between biotech firms and academic institutions are accelerating innovation, driving the market forward. Regulatory support for gene therapy approvals is another significant driver, as streamlined pathways encourage faster market entry. The rising prevalence of genetic disorders and rare diseases underscores the need for personalized therapies, further boosting demand. Moreover, patient-centric approaches are gaining traction, emphasizing tailored treatments that improve outcomes and patient satisfaction. Opportunities abound in emerging markets, where healthcare infrastructure is improving and awareness of genetic therapies is growing. Companies that can navigate regulatory landscapes and offer cost-effective solutions are poised to capture significant market share. The personalized gene therapies market is set for sustained growth, driven by technological breakthroughs and a focus on individualized care.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Somatic Gene Therapy
    • 4.1.2 Germline Gene Therapy
    • 4.1.3 In Vivo Gene Therapy
    • 4.1.4 Ex Vivo Gene Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Viral Vectors
    • 4.2.2 Non-Viral Vectors
    • 4.2.3 Gene Editing Tools
    • 4.2.4 Plasmid DNA
    • 4.2.5 RNA Therapeutics
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genetic Screening
    • 4.3.2 Consulting
    • 4.3.3 Custom Gene Synthesis
    • 4.3.4 Clinical Trials
    • 4.3.5 Regulatory Support
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR
    • 4.4.2 TALENs
    • 4.4.3 Zinc Finger Nucleases
    • 4.4.4 Antisense Oligonucleotides
    • 4.4.5 RNA Interference
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Rare Diseases
    • 4.5.3 Cardiovascular
    • 4.5.4 Neurological Disorders
    • 4.5.5 Ophthalmology
    • 4.5.6 Metabolic Disorders
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Pharmaceutical Companies
    • 4.6.4 Research Institutes
    • 4.6.5 Academic Institutions
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Gene Delivery
    • 4.7.2 Gene Editing
    • 4.7.3 Gene Silencing
    • 4.7.4 Gene Replacement
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Clinical
    • 4.8.2 Commercial
    • 4.8.3 Research
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Discovery
    • 4.9.2 Preclinical
    • 4.9.3 Clinical Trials
    • 4.9.4 Commercialization

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Bluebird Bio
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Sangamo Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 uni Qure
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 REGENXBIO
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Krystal Biotech
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Orchard Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Logic Bio Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Passage Bio
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Intellia Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Editas Medicine
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Beam Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Precision Bio Sciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 CRISPR Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Rubius Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Homology Medicines
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Repligen
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Voyager Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Cellectis
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Meira GTx
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Freeline Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us